Up­dat­ed: No­vo Hold­ings pays $16.5B to take Catal­ent pri­vate — and sells three man­u­fac­tur­ing sites to No­vo Nordisk

No­vo Hold­ings, the in­vest­ment arm of No­vo Nordisk’s par­ent foun­da­tion, is buy­ing Catal­ent in a deal val­ued at $16.5 bil­lion, the biggest it’s ever made.

Catal­ent, a ma­jor play­er in the con­tract de­vel­op­ment and man­u­fac­tur­ing world, is heav­i­ly in­volved in pro­duc­ing No­vo Nordisk’s top-sell­ing obe­si­ty drug We­govy, which con­tin­ues to be in short­age. As part of the all-cash deal, No­vo Hold­ings will sell three Catal­ent fill-fin­ish sites and re­lat­ed as­sets to No­vo Nordisk in Italy, Bel­gium and Bloom­ing­ton, IN.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER